News

Jushi Holdings Inc. to Report Second Quarter 2023 Financial Results on August 11, 2023

BOCA RATON, Fla., July 28, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

1 year ago

Press release: Online availability of Sanofi’s half-year financial report for 2023

Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces that its half-year financial report…

1 year ago

Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

1 year ago

Biogen to Acquire Reata Pharmaceuticals

SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia  Proposed acquisition represents meaningful step forward…

1 year ago

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics…

1 year ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading…

1 year ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA…

1 year ago

Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023

SAN FRANCISCO, July 28, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation…

1 year ago

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study…

1 year ago

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

TORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

1 year ago